Rivaroxaban treatment among children with cancer-associated thromboembolism: Real-world data

Assaf Arie Barg*, Sarina Levy-Mendelovich, Oded Gilad, Joanne Yacobovich, Ilia Tamarin, Ivan Budnik, Hana Golan, Amos Toren, Gili Kenet

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

This is the first study examining real-life data of pediatric cancer patients treated with rivaroxaban. Children with thrombocytopenia and high bleeding risk were excluded from previous clinical trials. Data regarding the safety and efficacy of rivaroxaban in pediatric cancer-associated thrombosis are scarce. Our case series included 16 children aged 7.5–17 years. Thrombus resolution rate in our study was comparable to results of previous studies. However, higher rates of thrombotic and bleeding complications were seen in our study as compared to previous reports, especially among patients with relapsed or refractory disease.

Original languageEnglish
Article numbere29888
JournalPediatric Blood and Cancer
Volume69
Issue number10
DOIs
StatePublished - Oct 2022

Funding

FundersFunder number
Alnylam
BPL
Pfizer
Bayer
Shire
CSL Limited

    Keywords

    • cancer
    • pediatric
    • rivaroxaban
    • thrombosis

    Fingerprint

    Dive into the research topics of 'Rivaroxaban treatment among children with cancer-associated thromboembolism: Real-world data'. Together they form a unique fingerprint.

    Cite this